Treatment of regorafenib in patients with metastatic or unresectable gastrointestinal stromal tumor after failure of imatinib and sunitinib

Yurina Saito, Tsuyoshi Takahashi, Koji Tanaka, Yasuhiro Miyazaki, Tomoki Makino, Yukinori Kurokawa, Makoto Yamasaki, Kiyokazu Nakajima, Shuji Takiguchi, Masaki Mori, Yuichiro Doki

研究成果: Contribution to journalReview article査読

3 被引用数 (Scopus)

抄録

Imatinib mesylate has dramatically improved the survival with unresectable or metastatic GIST, whereas many patients subsequently develop imatinib resistance. Followed by sunitinib, regorafenib has been approved since 2013 in Japan. We aimed to assess efficacy and safety of regorafenib in GIST patients in clinical setting. The study was conducted between August 2013 and April 2016, among 11 patients with GIST treated by regorafenib. The median treatment duration was 8.4 months. The median progression-free survival (PFS) was 7.4 months. Nine patients experienced at least one Grade 3 or 4 toxicity from regorafenib. The most common Grade 3 toxicity was hand-and-foot skin reactions (4 of 11; 36.4%), followed by hypertension (3 of 11; 27.3%). Dose reduction was required in 8 patients. Although dose modifications due to toxicities were very common, some patients achieved long PFS with regorafenib treatment.

本文言語英語
ページ(範囲)121-123
ページ数3
ジャーナルJapanese Journal of Cancer and Chemotherapy
45
1
出版ステータス出版済み - 1 2018
外部発表はい

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

フィンガープリント 「Treatment of regorafenib in patients with metastatic or unresectable gastrointestinal stromal tumor after failure of imatinib and sunitinib」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル